Maximum quantity allowed is 999
	  Please select the quantity
	
CAS RN: 888504-28-7 | Product Number: P2220
Potassium 5-Methyl-1,3,4-oxadiazole-2-carboxylate
 
									 
							Purity: >98.0%(T)(HPLC)
Synonyms:
						
						- 5-Methyl-1,3,4-oxadiazole-2-carboxylic Acid Potassium Salt
Product Documents:
                    
				| Size | Unit Price | Same Day | 2-3 Business Days | Other Lead Time | Shipping Information   | 
|---|---|---|---|---|---|
| 200MG | 
                                                NT$1,218 | 11 | 1 | Contact Us | |
| 1G | 
                                                NT$4,746 | 15 | 0 | Contact Us | 
                		* The above prices include freight cost, customs, and other charges to the destination except for products that need to be shipped by sea or dry ice. For details, please contact 
                            our distributor
                        in Taiwan to order our product.
                		* The storage conditions are subject to change without notice.
| Product Number | P2220 | 
| Purity / Analysis Method   | >98.0%(T)(HPLC) | 
| Molecular Formula / Molecular Weight | C__4H__3KN__2O__3 = 166.18 | 
| Physical State (20 deg.C) | Solid | 
| Storage Temperature   | Room Temperature (Recommended in a cool and dark place, <15°C) | 
| CAS RN | 888504-28-7 | 
| Reaxys Registry Number | 14557884 | 
| PubChem Substance ID | 354334121 | 
| MDL Number | MFCD08060085 | 
Specifications
		  | Appearance | White to Almost white powder to crystal | 
| Purity(HPLC) | min. 98.0 area% | 
| Purity(Nonaqueous Titration) | min. 98.0 % | 
| NMR | confirm to structure | 
		Properties (reference)
	 
						 GHS
						  
								 Related Laws: 
							    
						Transport Information:
							| H.S.code* | 2934.99-000 | 
			Application
		
			A Synthetic Intermediate of Raltegravir
		
		This product is used for the synthesis of raltegravir which is an HIV integrase inhibitor used for the treatment of human immunodeficiency virus (HIV) infection.
References
- Discovery of Raltegravir, a Potent, Selective Orally Bioavailable HIV-Integrase Inhibitor for the Treatment of HIV-AIDS Infection
- Development of a Second-Generation, Highly Efficient Manufacturing Route for the HIV Integrase Inhibitor Raltegravir Potassium
- Identification, Synthesis, and Strategy For Minimization of Potential Impurities Observed In Raltegravir Potassium Drug Substance
			PubMed Literature
		Product Documents (Note: Some products will not have analytical charts available.)
 		Safety Data Sheet (SDS)
                	  
                      
						Please select Language.
		         
                 
        			
					The requested SDS is not available.
Please Contact Us for more information.
Specifications
C of A & Other Certificates
				     
						
						
						
							Please enter Lot Number
						
							Incorrect Lot Number. Please input only the 4-5 alphanumeric characters before the hyphen.
                        
				
                
	         	
                
                
    		Sample C of A
                    This is a sample C of A and may not represent a recently manufactured lot of the product.
	         	
                A sample C of A for this product is not available at this time.
Analytical Charts
					 
			  
		  
                                			
                                				        
                                						
                                						
                                						
                                							Please enter Lot Number
                                						
                                							Incorrect Lot Number. Please input only the 4-5 alphanumeric characters before the hyphen.
                                						
                                				
                                				
                                	         	
                                                
                                                    The requested analytical chart is not available. Sorry for the inconvenience.

 
       
	